"Bye-bye BPH symptoms" ad in the February issue of Urology cited by FDA in an April 2 letter for suggesting that "patients will no longer experience the symptoms of benign prostatic hyperplasia." In addition, FDA said the ad minimizes bolded warnings in Cardura labeling about syncope and hypotension. Pfizer also received a letter for a Trovan (trovafloxacin/alatrofloxacin) reminder ad in the February issue of Physician Assistant Journal. The journal ad contained a "pictorial representation of the lungs" and the claim "over one million prescriptions written." FDA said that "these expressed and implied claims are clear representations about the product, and thus would cause the ad to be considered a full product" ad, requiring brief summary. Both matters have been resolved with the agency, Pfizer said
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth